Predictive value of PIK3CA mutations for response to CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis. This is an ASCO ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PARK CITY, Utah — In this Healio Video Perspective from ...
JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...
Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...
– Data support casdozo as a promising novel immuno-oncology agent with clinical activity in liver cancer that may be associated with IL-27 pathway biomarkers – – Data support continued evaluation of ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco ...
4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results